Although the therapeutic misconception (TM) has been well described over a period of approximately 20 years, there has been disagreement about its implications for informed consent to research. In this paper we review some of the history and debate over the ethical implications of TM but also bring a new perspective to those debates. Drawing upon our experience of working in the context of translational research for rare childhood diseases such as Duchenne muscular dystrophy, we consider the ethical and legal implications of the TM for parental consent to research. In this situation, it is potentially the parent who is vulnerable to TM. In our analysis we not only consider the context of informed consent for research but also the wider environment in which the value of research is promoted, more broadly through the media but also more specifically through the communication strategies of patient organizations. All dissemination about developments in research for health runs the risk of portraying an overly optimistic view of the promise of biotechnological solutions and has the potential to encourage a ‘collective’ TM. In this paper we consider the challenge that TM presents to parents as well as explore the ethical and legal responsibilities of researchers to ensure an appropriately informed consent: compatible with a hopeful disposition of parents who consent for the their children whilst avoiding a blind and misleading optimism.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Abresch, R. T., Seyden, N. K., et al. (1998). Quality of life. Issues for persons with neuromuscular diseases. Physical Medicine and Rehabilitation Clinics of North America, 9(1), 233–248.
Action Duchenne: http://www.actionduchenne.org/. Accessed at 25 Nov 2011.
Ahlstrom, G., & Sjoden, P. O. (1996). Coping with illness-related problems and quality of life in adult individuals with muscular dystrophy. Journal of Psychosomatic Research, 41(4), 365–376.
Allied Control Council. (1949). Trials of war criminals before the Nuremberg military tribunals under control council law no. 10 (pp. 181–182) Washington, DC: US Government Printing Office.
Appelbaum, P. S., & Lidz, C. W. (2006). Re-evaluating the therapeutic misconception: Response to Miller and Joffe. Kennedy Institute of Ethics Journal, 16(4), 367–373.
Appelbaum, P. S., Roth, L. H., et al. (1982). The therapeutic misconception—Informed consent in psychiatric research. International Journal of Law and Psychiatry, 5(3–4), 319–329.
Appelbaum, P. S., Roth, L. H., et al. (1987). False hopes and best data—Consent to research and the therapeutic misconception. Hastings Center Report, 17(2), 20–24.
Appelbaum, P. S., Lidz, C. W., & Grisso, T. (2004). Therapeutic misconception in clinical research: Frequency and risk factors. IRB: Ethics and Human Research, 26(2), 1–8.
Bamberg, M., & Budwig, N. (1992). Therapeutic misconceptions: When the voices of caring and research are misconstrued as the voice of curing. Ethics and Behavior, 2(3), 165–184.
Bostrom, K., & Ahlstrom, G. (2004). Living with a chronic deteriorating disease: The trajectory with muscular dystrophy over ten years. Disability and Rehabilitation, 26(23), 1388–1398.
Bothwell, J. E., Dooley, J. M., et al. (2002). Duchenne muscular dystrophy—Parental perceptions. Clinical Pediatrics, 41(2), 105–109.
Boyer, F., Drame, M., et al. (2006). Factors relating to carer burden for families of persons with muscular dystrophy. Journal of Rehabilitation Medicine, 38(5), 309–315.
Braude, P., Minger, S. L., & Warwick, R. M. (2005). Stem cell therapy: Hope or hype? British Medical Journal, 330(7501), 1159–1160.
Buxton, J. (2007). Animal egg stem cell research plans in jeopardy. BioNews, 390. Website. Retrieved 9 February 2012, from http://www.bionews.org.uk/page_12949.asp.
Cave, E. (2010). Seen but not heard: Children in clinical trials. Medical Law Review, 18(1), 1–27.
de Melo-Martın, I., & Ho, A. (2008). Beyond informed consent: The therapeutic misconception and trust. Journal of Medical Ethics, 34, 202–205.
Department of Health. (2000). Stem cell research: Medical progress with responsibility. London, Crown Copyright.
Dixon-Woods, M., Ashcroft, R. E., et al. (2007). Beyond ‘misunderstanding’: Written information and decisions about taking part in a genetic epidemiology study. Social Science and Medicine, 65(2007), 2212–2222.
Doyal, L., & Tobias, J. (Eds.). (2000). Informed consent in medical research (pp. 286–292). London: BMJ Books.
Dresser, R. (2001). When science offers salvation: Patient advocacy and research ethics. New York: Oxford University Press.
Dresser, R. (2002). The ubiquity and utility of the therapeutic misconception. Social Philosophy & Policy, 19, 271–294.
Edsall, G. (1971). Experiments at Willowbrook. Lancet, 298(7715), 95.
Eggers, S., & Zatz, M. (1998). Social adjustment in adult males affected with progressive muscular dystrophy. American Journal of Medical Genetics, 81(1), 4–12.
Faden, R. R., & Beauchamp, T. L. (1986). A history and theory of informed consent. Oxford: Oxford University Press.
Gagliardi, B. A. (1991). The impact of Duchenne muscular dystrophy on families. Orthopaedic Nursing, 10(5), 41–49.
Geesink, I., Prainsack, B., & Franklin, S. (2008). Stem cell stories 1998–2008. Science as Culture, 17(1), 1–11.
General Medical Council. (2002). The role and responsibility of doctors. London: General Medical Council.
General Medical Council. (2007). 0–18 years: Guidance for doctors. London: General Medical Council.
General Medical Council. (2010). Good practice in research. London: General Medical Council.
Gibson, B. E., Young, N. L., et al. (2007). Men on the margin: A Bourdieusian examination of living into adulthood with muscular dystrophy. Social Science and Medicine, 65(3), 505–517.
Goldby, S. (1971). Experiments at the Willowbrook state school. Lancet, 297(7702), 749.
Hadskis, M., Kenny, N., Downie, J., Schmidt, M., & D’Arcy, R. (2008). The therapeutic misconception: A threat to valid parental consent for paediatric neuroimaging research. Accountability in Research, 15(3), 133–151.
Hagger, L. (2009). The child as vulnerable patient: Protection and empowerment. Aldershot: Ashgate Publishing.
Hagger, L., & Woods, S. (2005). Children in research: A risk of double jeopardy. International Journal of Children’s Rights, 13, 47–68.
Harris, J. (2003). Consent and end of life decisions. Journal of Medical Ethics, 29, 10–15.
Henderson, G. E., Easter, M. M., Zimmer, C., et al. (2006). Therapeutic misconception in early phase gene transfer trials. Social Science and Medicine, 62, 239–253.
Henderson, G. E., Churchill, L. R., Davis, M. R., Easter, M. M., Grady, C., Joffe, S., et al. (2007). Clinical trials and medical care: Defining the therapeutic misconception. PLoS Medicine, 4(11), 1735–1738.
Henderson, R. A. (2008) Consent, choice and children in research: Exploring decision-making by parents of children with Duchenne Muscular Dystrophy considering participation in genetic research projects. Unpublished PhD thesis, University of Newcastle UK.
Horng, S., & Grady, C. (2003). Misunderstanding in clinical research: Distinguishing therapeutic misconception, therapeutic misestimation, and therapeutic optimism. IRB, 25(1), 11–16.
Horrobin, D. F. (2003). Modern biomedical research: An internally self-consistent universe with little contact with medical reality?. February: Nature Reviews Drug Discovery.
James, A. (2008). Responsibility, children and childhood. In J. Bridgeman, H. Keating, & C. Lind (Eds.), Responsibility, law and the family (pp. 145–165). Aldershot: Ashgate Publishing.
Jansen, L. A. (2006). The problem with optimism in clinical trials. IRB, 28, 13–19.
Jansen, L. A. (2011). Two concepts of therapeutic optimism. Journal of Medical Ethics, 37, 563–566.
Joffe, S., Cook, E. F., Cleary, P. D., Clark, J. W., & Weeks, J. C. (2001). Quality of informed consent in cancer clinical trials: A cross-sectional survey. Lancet, 358, 1772–1777.
Joffe, S., & Miller, F. G. (2006). Rethinking risk benefit assessment for phase I cancer trials. Journal of Clinical Oncology, 24, 2987–2990.
Kodish, E., Eder, M., Noll, R. B., Ruccione, K., et al. (2004). Communication of randomization in childhood leukemia trials. Journal of the American Medical Association, 291(4), 470–475.
Lidz, C. W. (2006). The therapeutic misconception and our models of competency and informed consent. Behavioral Sciences and the Law, 24, 535–546.
Manson, N. C., & O’Neill, O. (2007). Rethinking informed consent in bioethics. Cambridge: Cambridge University Press.
Marcel, G. (1995). The philosophy of existentialism (trans: Manya Harari.) New York, NY: Carol Publishing Group.
Martin, P., & Nightingale, P. (2004). The myth of the biotech revolution. Trends in Biotechnology, 22(11), 564–569.
Meisel, A., Roth, L., & Lidz, C. (1977). Towards a model of the legal doctrine of informed consent. American Journal of Psychiatry, 134(3), 285–289.
Miller, M. (2000). Phase I cancer trials. A collusion of misunderstanding. Hastings Cent Rep, 30, 34–43.
Muscular Dystrophy Association: http://quest.mda.org/news/research-briefs-dmd-bmd-trials-update. Accessed at 25 Nov 2011.
National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. (1979). Belmont report: Ethical principles and guidelines for the protection of human subjects of research. Washington, DC.
Natterlund, B., Sjoden, P. O., et al. (2001). The illness experience of adult persons with muscular dystrophy. Disability and Rehabilitation, 23(17), 788–798.
NHS Executive. (2003). West midlands regional office report of a Review of the research framework in north staffordshire hospital NHS trust http://www.doh.gov.uk/wmro/nrthstaffs.htm. Accessed 25 Nov 2011.
O’Neill, O. (2002). Autonomy and trust in bioethics. Cambridge: Cambridge University Press.
Parent Project Muscular Dystrophy: http://www.parentprojectmd.org/site/PageServer?pagename=nws_index. Accessed at 25 Nov 2011.
Pattinson, S. D. (2011). Medical law and ethics. London: Sweet and Maxwell.
Pohlschmidt, M., & Meadowcroft, R., (2010). Muscle disease: The impact. Incidence and prevalence of neuromuscular conditions in the UK (p. 15) London, Muscular Dystrophy Campaign.
Reeve, C. (2005). CRF position statement on human embryonic stem cell research. Christopher and Dana Reeve Foundation: 2005.
Reynolds, W. W., & Nelson, R. M. (2007). Risk perception and decision processes underlying informed consent to research participation. Social Science & Medicine, 65, 2105–2115.
Sammons, H. (2009). (2009) Ethical issues of clinical trials in children: A European perspective. Archives of Disease in Childhood, 94, 474–477.
Samson, A., Tomiak, E., et al. (2009). The lived experience of hope among parents of a child with Duchenne muscular dystrophy: Perceiving the human being beyond the illness. Chronic Illness, 5, 103–114.
Saver, R. S. (2006). Medical research and intangible harm. University of Cincinnati Law Review, 74, 941–1012.
Shilling, V., Young, B. (2009). How do parents experience being asked to enter a child in a randomised controlled trial? BMC Medical Ethics, 10, 1. doi:10.1186/1472-6939-10-1. http://www.biomedcentral.com/1472-6939/10/1.
Siminoff, L., & Simon, C. (2004). A comparison of the informed consent process in paediatric and adult oncology. Philadelphia, PA: American Society of Bioethics and the Humanities.
Smith, R. (2000). Babies and consent: Yet another NHS scandal. British Medical Journal, 299, 1253.
Sorapop, K., & Douglas, S. (2009). Monitoring and regulating offshore stem cell clinics. Science, 323(5921), 1564–1565.
Stephenson, T. (2005). How children’s responses to drugs differ from adults. British Journal of Clinical Pharmacology, 59(6), 670–673.
Treanor, B. (2010). In G. (-Honore) Marcel, E. N. Zalta (Ed.), The stanford encyclopaedia of philosophy (Fall 2010 Edition) http://plato.stanford.edu/archives/fall2010/entries/marcel/.
TREAT-NMD. (2009). Therapeutic Misconception. TREAT-NMD International Conference: Bringing down the barriers in translational medicine in neuromuscular disorders. Brussels. Website. Retrieved 21 September 2011, from http://www.treat-nmd-conference.org/brussels-2009/2009-questions-received/2009-questions-the-therapeutic-misconception.
TREAT-NMD. (2010). Website. Retrieved 21 September 2010, from http://www.treat-nmd.eu/home.php.
Williams-Jones, B., & Corrigan, O. (2003). Rhetoric or hype: Where’s the ‘ethics’ in pharmacogenomics? American Journal of Pharmacogenomics, 3(6), 375–383.
Woods, S. (2008). Stem cell stories: From bedside to bench. Journal of Medical Ethics, 34(12), 845–848.
Woods, S., & McCormack, P. (2011). Disputing the ethics of research: The challenge from bioethics and patient activism to the interpretation of the Declaration of Helsinki in clinical trials. Bioethics (in press).
European Union Legislation
Regulation (EEC) No 1768/92.
Regulation (EC) No 1901/2006 (Medicinal products for paediatric use).
Directive 2001/20/EC (Clinical trials directive).
Regulation (EC) No 726/2004.
Children’s Act 1989.
Medicines for Human Use (Clinical Trials) Regulations 2004.
Mental Capacity Act 2005.
Mental Capacity Act 2005 Code of Practice.
Bolam v Friern Management Committee (1957) 1 WLR 582.
S v S (1972) AC 24.
Chatterton v Gerson (1981) QB 432.
Sidaway v Board of Governors of the Bethlem Royal Hospital and the Maudsley Hospital (1985) AC 871.
Gillick v West Norfolk and Wisbech Area Health Authority (1986) AC 112.
In Re Cincinnati Radiation Litig 874 F Supp 796 (SD Ohio 1995).
Re Y (1997) 2 WLR 556.
Bolitho (Deceased) v City and Hackney Health Authority (1998) AC 232.
Pearce v United Bristol Healthcare Trust (1999) PIQR 53.
Pretty v United Kingdom (2002) 35 EHRR 1.
R v Portsmouth NHS Trust ex p. Glass (1999) 2 FLR 905.
Re A (Male Sterilisation) (2000) 1 FLR 549.
Chester v Afshar (2005) 1 AC 134.
Mabon v Mabon et al. (2005) 3 WLR 460.
Re B (Adult, refusal of medical treatment) (2002) 2 All ER 449.
European Commission. (2008). Ethical considerations for clinical trials on medicinal products conducted with the paediatric population. ftp://ftp.cordis.europa.eu/pub/fp7/docs/ethical-considerations-paediatrics_en.pdf. Accessed 12 Nov 2011.
Parliamentary Office of Science and Technology. (2006). Postnote No. 266. Children’s medicines. http://www.parliament.uk/documents/post/postpn266.pdf. Accessed 14 Nov 2011.
TREAT-NMD is funded by the EU via FP6 under contract number LSHM-CT-2006-036825.
About this article
Cite this article
Woods, S., Hagger, L.E. & McCormack, P. Therapeutic Misconception: Hope, Trust and Misconception in Paediatric Research. Health Care Anal 22, 3–21 (2014). https://doi.org/10.1007/s10728-012-0201-8
- Informed consent
- Clinical trials
- Therapeutic misconception